The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic impact of immune-related adverse events with nivolumab in patients with advanced gastric cancer: A multicenter retrospective analysis.
 
Yuno Ohya
No Relationships to Disclose
 
Takayuki Ando
Speakers' Bureau - Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda
 
Akira Ueda
No Relationships to Disclose
 
Kohei Ogawa
No Relationships to Disclose
 
Iori Motoo
No Relationships to Disclose
 
Shinya Kajiura
No Relationships to Disclose
 
Kenichiro Tsukada
No Relationships to Disclose
 
Takuo Hara
No Relationships to Disclose
 
Nobuhiro Suzuki
No Relationships to Disclose
 
Naokatsu Nakada
No Relationships to Disclose
 
Shunsuke Takatori
No Relationships to Disclose
 
Naoki Horikawa
No Relationships to Disclose
 
Tsutomu Fujii
Honoraria - Asahi Kasei; Asahi Kasei; Asahi Kasei; Asahi Kasei; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Covidien/Medtronic; Covidien/Medtronic; Covidien/Medtronic; Covidien/Medtronic; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; EA Pharma; EA Pharma; EA Pharma; EA Pharma; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Kaken Pharmaceutical; Kaken Pharmaceutical; Kaken Pharmaceutical; Kaken Pharmaceutical; KCI; KCI; KCI; KCI; Lilly; Lilly; Lilly; Lilly; Miyarisan pharmaceutical; Miyarisan pharmaceutical; Miyarisan pharmaceutical; Miyarisan pharmaceutical; Mylan; Mylan; Mylan; Mylan; Otsuka; Otsuka; Otsuka; Otsuka; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; TERUMO; TERUMO; TERUMO; TERUMO; Tsumura & Co.; Tsumura & Co.; Tsumura & Co.; Tsumura & Co.
Research Funding - Asahi Kasei (Inst); Asahi Kasei (Inst); Asahi Kasei (Inst); Asahi Kasei (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Central Medical (Inst); Central Medical (Inst); Central Medical (Inst); Central Medical (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Covidien/Medtronic (Inst); Covidien/Medtronic (Inst); Covidien/Medtronic (Inst); Covidien/Medtronic (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); EA Pharma (Inst); EA Pharma (Inst); EA Pharma (Inst); EA Pharma (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Johnson & Johnson (Inst); Johnson & Johnson (Inst); Johnson & Johnson (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); Kaken Pharmaceutical (Inst); Kaken Pharmaceutical (Inst); Kaken Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Kyowa Hakko Kirin (Inst); Kyowa Hakko Kirin (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Miyarisan pharmaceutical (Inst); Miyarisan pharmaceutical (Inst); Miyarisan pharmaceutical (Inst); Miyarisan pharmaceutical (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Nihonkayaku (Inst); Nihonkayaku (Inst); Nihonkayaku (Inst); Nihonkayaku (Inst); Otsuka (Inst); Otsuka (Inst); Otsuka (Inst); Otsuka (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Shionogi (Inst); Shionogi (Inst); Shionogi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); TERUMO (Inst); TERUMO (Inst); TERUMO (Inst); TERUMO (Inst); Tsumura & Co. (Inst); Tsumura & Co. (Inst); Tsumura & Co. (Inst); Tsumura & Co. (Inst)
 
Ichiro Yasuda
No Relationships to Disclose